Cargando…
Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial
BACKGROUND: This study tested whether early left intracoronary arterial (LAD) administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs, called OmniMSCs) in acute ST-segment elevation myocardial infarction (STEMI) of Lee-Sung pigs induced by 90 min balloon-occluded LAD was safe and...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091140/ https://www.ncbi.nlm.nih.gov/pubmed/37063964 http://dx.doi.org/10.3389/fcvm.2023.1153428 |
_version_ | 1785023091920863232 |
---|---|
author | Chen, Wannhsin Hou, Chun-Hsiang Chen, Yi-Ling Shen, Hsin-Hsin Lin, Chen-Hsuan Wu, Cheng-Yi Lin, Meng-Hsueh Liao, Chih-Ching Huang, Jun-Jae Yang, Chi-Yu Li, Yi-Chen Yip, Hon-Kan |
author_facet | Chen, Wannhsin Hou, Chun-Hsiang Chen, Yi-Ling Shen, Hsin-Hsin Lin, Chen-Hsuan Wu, Cheng-Yi Lin, Meng-Hsueh Liao, Chih-Ching Huang, Jun-Jae Yang, Chi-Yu Li, Yi-Chen Yip, Hon-Kan |
author_sort | Chen, Wannhsin |
collection | PubMed |
description | BACKGROUND: This study tested whether early left intracoronary arterial (LAD) administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs, called OmniMSCs) in acute ST-segment elevation myocardial infarction (STEMI) of Lee-Sung pigs induced by 90 min balloon-occluded LAD was safe and effective. METHODS AND RESULTS: Young male Lee-Sung pigs were categorized into SC (sham-operated control, n = 3), AMI-B (STEMI + buffer/21 cc/administered at 90 min after STEMI, n = 6), and AMI-M [acute myocardial infarction (AMI) + hBMMSCs/1.5 × 10(7)/administered at 90 min after STEMI, n = 6] groups. By 2 and 5 months after STEMI, the cardiac magnetic resonance imaging demonstrated that the muscle scar score (MSS) and abnormal cardiac muscle exercise score in the infarct region were significantly increased in the AMI-B than in the SC group that were significantly reversed in the AMI-M group, whereas the left ventricular ejection function by each month (from 1 to 5) displayed an opposite pattern of MSS among the groups (all p < 0.001). By 5 months, histopathological findings of infarct and fibrosis areas and isolectin-B4 exhibited an identical pattern, whereas the cellular expressions of troponin-I/troponin-T/von Willebrand factor exhibited an opposite pattern of MSS among the groups (all p < 0.001). The ST-segment resolution (>80%) was significantly earlier (estimated after 6-h AMI) in the AMI-M group than in the AMI-B group (p < 0.001). The protein expressions of inflammation (IL-1β/TNF-α/NF-κB)/oxidative stress (NOX-1/NOX-2/oxidized protein)/apoptosis (cleaved caspase-3/cleaved PARP)/DNA damage (γ-H2AX) displayed an identical pattern to MSS among the groups, whereas the protein expressions of angiogenesis factors (SDF-1α/VEGF) were significantly and progressively increased from SC, AMI-B, to AMI-M groups (all p < 0.001). CONCLUSION: Early intra-LAD transfusion of OmniMSC treatment effectively reduced the infarct size and preserved LV function in porcine STEMI. |
format | Online Article Text |
id | pubmed-10091140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100911402023-04-13 Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial Chen, Wannhsin Hou, Chun-Hsiang Chen, Yi-Ling Shen, Hsin-Hsin Lin, Chen-Hsuan Wu, Cheng-Yi Lin, Meng-Hsueh Liao, Chih-Ching Huang, Jun-Jae Yang, Chi-Yu Li, Yi-Chen Yip, Hon-Kan Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: This study tested whether early left intracoronary arterial (LAD) administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs, called OmniMSCs) in acute ST-segment elevation myocardial infarction (STEMI) of Lee-Sung pigs induced by 90 min balloon-occluded LAD was safe and effective. METHODS AND RESULTS: Young male Lee-Sung pigs were categorized into SC (sham-operated control, n = 3), AMI-B (STEMI + buffer/21 cc/administered at 90 min after STEMI, n = 6), and AMI-M [acute myocardial infarction (AMI) + hBMMSCs/1.5 × 10(7)/administered at 90 min after STEMI, n = 6] groups. By 2 and 5 months after STEMI, the cardiac magnetic resonance imaging demonstrated that the muscle scar score (MSS) and abnormal cardiac muscle exercise score in the infarct region were significantly increased in the AMI-B than in the SC group that were significantly reversed in the AMI-M group, whereas the left ventricular ejection function by each month (from 1 to 5) displayed an opposite pattern of MSS among the groups (all p < 0.001). By 5 months, histopathological findings of infarct and fibrosis areas and isolectin-B4 exhibited an identical pattern, whereas the cellular expressions of troponin-I/troponin-T/von Willebrand factor exhibited an opposite pattern of MSS among the groups (all p < 0.001). The ST-segment resolution (>80%) was significantly earlier (estimated after 6-h AMI) in the AMI-M group than in the AMI-B group (p < 0.001). The protein expressions of inflammation (IL-1β/TNF-α/NF-κB)/oxidative stress (NOX-1/NOX-2/oxidized protein)/apoptosis (cleaved caspase-3/cleaved PARP)/DNA damage (γ-H2AX) displayed an identical pattern to MSS among the groups, whereas the protein expressions of angiogenesis factors (SDF-1α/VEGF) were significantly and progressively increased from SC, AMI-B, to AMI-M groups (all p < 0.001). CONCLUSION: Early intra-LAD transfusion of OmniMSC treatment effectively reduced the infarct size and preserved LV function in porcine STEMI. Frontiers Media S.A. 2023-03-29 /pmc/articles/PMC10091140/ /pubmed/37063964 http://dx.doi.org/10.3389/fcvm.2023.1153428 Text en © 2023 Chen, Hou, Chen, Shen, Lin, Wu, Lin, Liao, Huang, Yang, Li and Yip. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Chen, Wannhsin Hou, Chun-Hsiang Chen, Yi-Ling Shen, Hsin-Hsin Lin, Chen-Hsuan Wu, Cheng-Yi Lin, Meng-Hsueh Liao, Chih-Ching Huang, Jun-Jae Yang, Chi-Yu Li, Yi-Chen Yip, Hon-Kan Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial |
title | Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial |
title_full | Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial |
title_fullStr | Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial |
title_full_unstemmed | Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial |
title_short | Safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in STEMI of Lee-Sung pigs—A preclinical study for supporting the feasibility of the OmniMSC-AMI phase I clinical trial |
title_sort | safety and efficacy of intracoronary artery administration of human bone marrow-derived mesenchymal stem cells in stemi of lee-sung pigs—a preclinical study for supporting the feasibility of the omnimsc-ami phase i clinical trial |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091140/ https://www.ncbi.nlm.nih.gov/pubmed/37063964 http://dx.doi.org/10.3389/fcvm.2023.1153428 |
work_keys_str_mv | AT chenwannhsin safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT houchunhsiang safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT chenyiling safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT shenhsinhsin safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT linchenhsuan safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT wuchengyi safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT linmenghsueh safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT liaochihching safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT huangjunjae safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT yangchiyu safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT liyichen safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial AT yiphonkan safetyandefficacyofintracoronaryarteryadministrationofhumanbonemarrowderivedmesenchymalstemcellsinstemiofleesungpigsapreclinicalstudyforsupportingthefeasibilityoftheomnimscamiphaseiclinicaltrial |